Approximately 90% of ovarian malignancies are epithelial ovarian cancer (EOC), with serous ovarian cancer (SOC) accounting for about 75% of EOC. In 2014, the World Health Organization (WHO) classified SOC into Type I and Type II based on histological findings under ordinary microscopy and biological behavior: Type I refers to low-grade serous ovarian cancer (LGSOC), and Type II is high-grade SOC (HGSOC). The molecular pathways, biological behavior, and clinical characteristics of HGSOC and LGSOC differ1.
